Survival after docetaxel for metastatic castration-resistant prostate cancer in a rural health care setting

Carsten Nieder; Luka Stanisavljevic; Astrid Dalhaug; Ellinor Haukland

doi:10.5114/wo.2024.138842

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2024
vol. 28

Send email

Copy url:

abstract:

Original paper

Survival after docetaxel for metastatic castration-resistant prostate cancer in a rural health care setting

Carsten Nieder

^{1, 2}

,

Luka Stanisavljevic

¹

,

Astrid Dalhaug

¹

,

Ellinor Haukland

^{1, 3}

Department of Oncology and Palliative Medicine, Nordland Hospital Trust, Bodø, Norway
Department of Clinical Medicine, Faculty of Health Sciences, UiT – The Arctic University of Norway, Tromsø, Norway
SHARE – Center for Resilience in Healthcare, Faculty of Health Sciences, Department of Quality and Health Technology, University of Stavanger, Stavanger, Norway

Contemp Oncol (Pozn) 2024; 28 (1): 31–36

DOI: https://doi.org/10.5114/wo.2024.138842

Online publish date: 2024/04/15

View full text Get citation

PlumX metrics:

Introduction:
The aim of this study was to evaluate overall survival of men who received systemic therapy with docetaxel for metastatic castration- resistant prostate cancer (MCRPC) in rural Nordland County, Norway. Prognostic factors related to treatment and other variables were evaluated.

Material and methods:
Overall, 132 patients were included in this retrospective study covering the years 2009–2022. Uni- and multivariate survival analyses were performed.

Results:
In this elderly cohort (median age 72 years), weekly low-dose docetaxel was the preferred regimen (44%). Seventy-three percent were treated in the first line. Only 11 patients (8%) were pre-exposed to docetaxel in the hormone-sensitive phase. Median survival was 14.3 months. Prognostic factors for longer survival included higher hemoglobin, lower lactate dehydrogenase, administration of docetaxel as first-line MCRPC treatment, and use of fewer prescription drugs for comorbidity. Pre-exposure to docetaxel did not play a major role, p = 0.76.

Conclusions:
In this rural health care setting, survival after docetaxel was shorter than reported by other groups. Blood test results were confirmed as important prognostic factors. In the present era of evolving treatment sequences, we recommend monitoring of real-world treatment results.

keywords:

Survival after docetaxel for metastatic castration-resistant prostate cancer in a rural health care setting

Carsten Nieder 1, 2 , Luka Stanisavljevic 1 , Astrid Dalhaug 1 , Ellinor Haukland 1, 3

prostate cancer, distant metastases, chemotherapy, systemic therapy, survival, pattern of care

Carsten Nieder

^{1, 2}

,

Luka Stanisavljevic

¹

,

Astrid Dalhaug

¹

,

Ellinor Haukland

^{1, 3}